NewcelX Ltd. (NCEL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

NewcelX Ltd. (NCEL) closed at USD 2.61 on 2026-10-14, a change of -75.1 % over the past year, with a market capitalization of USD 16.46M.

NewcelX Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NewcelX Ltd. key figures

Previous close

USD 2.61 (2026-10-14)

1-year change

-75.1 %

Market cap

USD 16.46M

Enterprise value

USD 15.03M

P/E ratio (trailing)

5.94

P/E ratio (forward)

-4.75

EPS (trailing)

0.48

EPS (forward)

-0.60

PEG ratio

n/a

Price to book

2.54

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.73

Employees

9

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NewcelX Ltd.

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NewcelX Ltd. and compare it with other stocks.